# EDGAR Filing Document

**Accession Number:** 0000748592
**File Stem:** 0001493152-26-005226
**Filing Date:** 2026-2
**Character Count:** 6907
**Document Hash:** 8536f64db7a532c7f5b33faf207ecfca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-005226.hdr.sgml**: 20260205

**ACCESSION NUMBER**: 0001493152-26-005226

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260205

**DATE AS OF CHANGE**: 20260205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11460
- **FILM NUMBER:** 26601313

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-A**

For Registration of Certain Classes of Securities

Pursuant to Section 12(b) or 12(g) of the

Securities Exchange Act of 1934

---

| |
|:---|
| **ERNEXA THERAPEUTICS INC.** |
| (Exact name of registrant as specified in its charter) |

---

<u>Delaware</u> <u>31-1103425</u> <br> (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

<u>1035 Cambridge Street, Suite 18A Cambridge, MA</u> <u>02141</u> <br> (Address of principal executive offices) (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class to be so registered | Name of each exchange on which each class is to be registered |
| Warrants, each warrant exercisable for one share of common stock, par value $0.005 per share | The Nasdaq Stock Market LLC |

---

If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this Form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333- 293150

Securities to be registered pursuant to Section 12(g) of the Act:

<u>None</u> <br> (Title of class)

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. <u>Description of the Registrant's Securities to be Registered.</u>

The securities to be registered hereby are Common Warrants of Ernexa Therapeutics Inc. (the "Company"). For a description of the Warrants, reference is made to the information under the heading "Description of the Securities to be Registered" included in the prospectus that constitutes a part of the Company's Registration Statement on Form S-1 (File No. 333-293150), dated February 5, 2026 (the "Registration Statement"), which information is incorporated herein by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.

Item 2. <u>Exhibits.</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by** | **Incorporated by** | | |
| | | **Reference** | **Reference** | **Filed or Furnished** | **Filed or Furnished** |
| <br>**Exhibit**<br>**Number** | <br>**Exhibit Description** | **Form** | **Exhibit** | **Filing Date** | **Herewith** |
| 3.1 | [Composite Restated Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/748592/000114036124013254/ef20015352_ex3-1.htm) | 10-K | 3.1 | 03/14/2024 |  |
| 3.2 | [Second Amended and Restated Bylaws of the Company](https://www.sec.gov/Archives/edgar/data/748592/000114036122036744/brhc10042808_ex3-2.htm) | 8-K | 3.2 | 10/11/2022 |  |
| 3.3 | [Certificate of Validation of Eterna Therapeutics Inc., as filed with the Secretary of State of the State of Delaware on September 3, 2021](https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex3-1.htm) | 8-K | 3.1 | 09/13/2021 |  |
| 3.4 | [Certificate of Amendment to the Company's Restated Certificate of Incorporation, effective March 26, 2025 (Name Change).](https://www.sec.gov/Archives/edgar/data/748592/000164117225000681/ex3-1.htm) | 8-K | 3.1 | 03/26/2025 |  |
| 3.5 | [Third Amended and Restated Bylaws of the Company](https://www.sec.gov/Archives/edgar/data/748592/000164117225000681/ex3-2.htm) | 8-K | 3.2 | 03/26/2025 |  |
| 3.6 | [Certificate of Amendment to the Company's Restated Certificate of Incorporation, filed June 2, 2025 (Authorized Shares).](https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/ex3-1.htm) | 8-K | 3.1 | 06/02/2025 |  |
| 3.7 | [Certificate of Amendment to the Company's Restated Certificate of Incorporation, filed June 2, 2025 (Written Consent).](https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/ex3-2.htm) | 8-K | 3.2 | 06/02/2025 |  |
| 3.8 | [Certificate of Amendment to the Company's Restated Certificate of Incorporation, filed June 10, 2025 (Reverse Stock Split).](https://www.sec.gov/Archives/edgar/data/748592/000164117225014877/ex3-1.htm) | 8-K | 3.1 | 06/12/2025 |  |
| 4.1 | [Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934](https://www.sec.gov/Archives/edgar/data/748592/000114036122014764/brhc10036185_ex4-1.htm) | 10-K | 4.1 | 04/15/2022 |  |
| 4.2 | [Form of Warrant](https://www.sec.gov/Archives/edgar/data/748592/000149315226005215/ex4-2.htm) | S-1 | 4.2 | 02/05/2026 |  |

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 5, 2026 |  |  |
|  |  | **ERNEXA THERAPEUTICS INC.** | **ERNEXA THERAPEUTICS INC.** |
|  |  | By: | */s/ Sanjeev Luther* |
|  |  | Name: | Sanjeev Luther |
|  |  | Title: | Chief Executive Officer |

---